109 related articles for article (PubMed ID: 32395382)
1. Erratum: Analysis of Tau Protein Expression in Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Different Molecular Subtypes of Breast Cancer.
Lei C; Yang C; Xia B; Ji F; Zhang Y; Gao H; Xiong Q; Lin Y; Zhuang X; Zhang L; Zhu T; Cheng M; Yang M; Wang K
J Breast Cancer; 2020 Apr; 23(2):230-231. PubMed ID: 32395382
[TBL] [Abstract][Full Text] [Related]
2. ERRATUM.
Int J Bioprint; 2020; 6(4):309. PubMed ID: 33102924
[TBL] [Abstract][Full Text] [Related]
3. Erratum: Role of Scintimammography in Assessing the Response of Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
World J Nucl Med; 2016; 15(1):75. PubMed ID: 26912988
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the pathological response and prognosis following neoadjuvant chemotherapy in molecular subtypes of breast cancer.
Zhao Y; Dong X; Li R; Ma X; Song J; Li Y; Zhang D
Onco Targets Ther; 2015; 8():1511-21. PubMed ID: 26150728
[TBL] [Abstract][Full Text] [Related]
5. Corrigendum.
Paediatr Child Health; 2015; 20(8):466-7. PubMed ID: 26744561
[TBL] [Abstract][Full Text] [Related]
6. [A study on the predictive and evaluational value of molecular subtypes and dynamic contrast-enhanced magnetic resonance imaging of neoadjuvant chemotherapy for breast cancer].
Liu WQ; Ye JM; Xu L; Liu Q; Zhao JX; Duan XN; Liu YH
Zhonghua Wai Ke Za Zhi; 2013 Aug; 51(8):706-9. PubMed ID: 24252676
[TBL] [Abstract][Full Text] [Related]
7. Molecular subtypes as a predictor of response to neoadjuvant chemotherapy in breast cancer patients.
Subbiah S; Gopu G; Senthilkumar P; Muniasamy P
Indian J Cancer; 2017; 54(4):652-657. PubMed ID: 30082552
[TBL] [Abstract][Full Text] [Related]
8. Tau expression correlated with breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy.
Wang K; Deng QT; Liao N; Zhang GC; Liu YH; Xu FP; Zu J; Li XR; Wu YL
Tumour Biol; 2013 Feb; 34(1):33-8. PubMed ID: 22976542
[TBL] [Abstract][Full Text] [Related]
9. The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients.
Mark KMK; Varn FS; Ung MH; Qian F; Cheng C
BMC Cancer; 2017 May; 17(1):306. PubMed ID: 28464832
[TBL] [Abstract][Full Text] [Related]
10. Tau proteins expressions in advanced breast cancer and its significance in taxane-containing neoadjuvant chemotherapy.
Li ZH; Xiong QY; Tu JH; Gong Y; Qiu W; Zhang HQ; Wei WS; Hou YF; Cui WQ
Med Oncol; 2013; 30(3):591. PubMed ID: 23681778
[TBL] [Abstract][Full Text] [Related]
11. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
12. Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy.
Liu S; Ren R; Chen Z; Wang Y; Fan T; Li C; Zhang P
J Magn Reson Imaging; 2015 Sep; 42(3):779-87. PubMed ID: 25580585
[TBL] [Abstract][Full Text] [Related]
13. Prediction of pathological response to neoadjuvant chemotherapy in breast cancer patients by imaging.
Kaise H; Shimizu F; Akazawa K; Hasegawa Y; Horiguchi J; Miura D; Kohno N; Ishikawa T
J Surg Res; 2018 May; 225():175-180. PubMed ID: 29605029
[TBL] [Abstract][Full Text] [Related]
14. The Effect of the Leptin and Leptin Receptor Expression on the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer.
Kong Y; Dong Q; Ji H; Sang M; Ding Y; Zhao M; Yang H; Geng C
Med Sci Monit; 2019 Apr; 25():3005-3013. PubMed ID: 31015393
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of associations between molecular subtypes and responses to neoadjuvant chemotherapy in primary breast cancer patients].
Zhou YJ; Ying M; He YJ; Liu YQ; Fan ZQ; Fan T; Li JF; Wang TF; Xie YT; Lu AP; Ouyang T
Zhonghua Yi Xue Za Zhi; 2013 Jun; 93(22):1711-5. PubMed ID: 24124677
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic accuracy of magnetic resonance imaging in predicting pathologic complete response after neoadjuvant chemotherapy in patients with different molecular subtypes of breast cancer.
Zhang X; Wang D; Liu Z; Wang Z; Li Q; Xu H; Zhang B; Liu T; Jin F
Quant Imaging Med Surg; 2020 Jan; 10(1):197-210. PubMed ID: 31956542
[TBL] [Abstract][Full Text] [Related]
18. Expression of BCRP/ABCG2 Protein in Invasive Breast Cancer and Response to Neoadjuvant Chemotherapy.
Zhang YS; Yang C; Han L; Liu L; Liu YJ
Oncol Res Treat; 2022; 45(3):94-101. PubMed ID: 34775385
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
20. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.
Bonnefoi H; Litière S; Piccart M; MacGrogan G; Fumoleau P; Brain E; Petit T; Rouanet P; Jassem J; Moldovan C; Bodmer A; Zaman K; Cufer T; Campone M; Luporsi E; Malmström P; Werutsky G; Bogaerts J; Bergh J; Cameron DA;
Ann Oncol; 2014 Jun; 25(6):1128-36. PubMed ID: 24618153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
